Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Zabludoff (San Diego, United States of America). Late Breaking Abstract - ND-L02-s0201 treatment leads to efficacy in preclinical IPF models. 881

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract: An animal model for studies on pathogenesis and pharmaceutical intervention of chronic asthma Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010 Late Breaking Abstract - Evaluating the feasibility, safety, and efficacy of senolytics in idiopathic pulmonary fibrosis Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings Year: 2019 Late Breaking Abstract - Survival and course of lung function in patients with idiopathic pulmonary fibrosis with or without antifibrotic treatment: long-term results of the INSIGHTS-IPF registry Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings Year: 2019 Late Breaking Abstract - The efficacy of roflumilast in the treatment of COPD(stage B). Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Late Breaking Abstract - Comparative real world effectiveness of triple therapy versus dual bronchodilation in frequently exacerbating patients with COPD Source: International Congress 2018 – COPD exacerbations and bronchiectasis Year: 2018 Late Breaking Abstract - Development of an ex vivo pediatric preclinical model of bronchopulmonary dysplasia for aerosol regional deposition studies Source: International Congress 2018 – New pharmacological strategies in airway diseases Year: 2018 Late Breaking Abstract - Promising results of the infliximab biosimilar Inflectra® in severe sarcoidosis patients Source: International Congress 2017 – The many faces of sarcoidosis Year: 2017 Late Breaking Abstract - iPREDICT: Pilot study to develop predictive model of changes in asthma control Source: International Congress 2019 – Lung function evaluation and prognosis of airway diseases Year: 2019 Late Breaking Abstract - Tiotropium/olodaterol improves pulmonary function in patients with treatment naive COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Late Breaking Abstract - Treatment with ATYR1923 reduces biomarkers in COVID-19 pneumonia Source: Virtual Congress 2021 – Diagnosis and management of COVID-19 Year: 2021 Late Breaking Abstract - 12-month lung clinical and functional consequences in patients with severe COVID-19 Source: Virtual Congress 2021 – Biological and functional markers of COVID-19 Year: 2021 Late Breaking Abstract - Development of a multivariate model for clinical prediction in COVID 19 infected patients . Source: Virtual Congress 2021 – Biological and functional markers of COVID-19 Year: 2021 Late Breaking Abstract - Effectiveness and safety of mepolizumab in real-world clinical practice: the REALITI-A study Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019 Late Breaking Abstract - A key endpoint in viral challenge models of asthma exacerbations Source: International Congress 2019 – Airway physiology Year: 2019 Late Breaking Abstract - Corticosteroid optimisation in severe asthma using composite biomarkers to adjust dose versus a symptom/risk-based algorithm Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020 Late Breaking Abstract - Relationship between clinical features and mortality in a cohort of COPD patients. Source: Virtual Congress 2021 – Prediction of exacerbations in patients with COPD Year: 2021 Late Breaking Abstract - The outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Late Breaking Abstract - Durable clinical benefit of benralizumab following oral corticosteroid reduction: The PONENTE study Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021 Late Breaking Abstract - Detection of clinical instability by eNose in COPD patients Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018 Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017